118 related articles for article (PubMed ID: 16785126)
1. Fatal course after administration of rituximab in a boy with relapsed all: a case report and review of literature.
Seifert G; Reindl T; Lobitz S; Seeger K; Henze G
Haematologica; 2006 Jun; 91(6 Suppl):ECR23. PubMed ID: 16785126
[TBL] [Abstract][Full Text] [Related]
2. Refractoriness to rituximab monotherapy in a child with relapsed/refractory Burkitt non-Hodgkin lymphoma.
Okur FV; Oguz A; Karadeniz C; Citak C; Poyraz A; Boyunaga O
Pediatr Hematol Oncol; 2006; 23(1):25-31. PubMed ID: 16326409
[TBL] [Abstract][Full Text] [Related]
3. Early relapse after rituximab chemoimmunotherapy.
Kiss F; Buslig J; Szegedi I; Scholtz B; Kappelmayer J; Kiss C
Pediatr Blood Cancer; 2008 Feb; 50(2):372-5. PubMed ID: 17973316
[TBL] [Abstract][Full Text] [Related]
4. [Effective combination chemotherapy with rituximab for acute lymphoblastic leukemia with bone relapse after bone marrow transplantation].
Abe T; Kitajima T; Honma K; Kurasaki T; Okazuka K; Shibasaki Y; Momoi A; Kuroha T; Masuko M; Yagisawa K; Furukawa T; Toba K; Aizawa Y
Rinsho Ketsueki; 2008 Nov; 49(11):1556-61. PubMed ID: 19047788
[TBL] [Abstract][Full Text] [Related]
5. Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with systemic anti-CD-20 (rituximab).
Kraal K; Schalij-Delfos N; van Buchem M; Egeler M; Ball L
Haematologica; 2005 Nov; 90 Suppl():ECR24. PubMed ID: 16266915
[TBL] [Abstract][Full Text] [Related]
6. [Cardiac effects of cytokines produced after rituximab infusion].
Tournamille JF; Rigal-Huguet F; Pathak A; Montastruc JL; Lapeyre-Mestre M
Bull Cancer; 2005 Sep; 92(9):769-71. PubMed ID: 16203266
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma.
de Vries MJ; Veerman AJ; Zwaan CM
Br J Haematol; 2004 May; 125(3):414-5. PubMed ID: 15086431
[No Abstract] [Full Text] [Related]
8. [Early relapse of Burkitt's lymphoma with t(8;14) and t(14;18) after rituximab-combined CODOX-M and IVAC therapy].
Fujishima N; Fujishima M; Inomata M; Yamanaka Y; Saitoh K; Kameoka Y; Yoshioka T; Saitoh H; Takahashi N; Hirokawa M; Sawada K
Rinsho Ketsueki; 2007 Apr; 48(4):326-31. PubMed ID: 17515125
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy for relapsed mediastinal B-cell lymphoma with allogeneic HLA-identical related donor bone marrow transplantation, donor lymphocyte infusion and IDEC-C2B8.
Ratei R; Matylis A; Krahl D; Arnold R; Stein H; Dörken B; Ludwig WD
Leuk Lymphoma; 2000 Dec; 40(1-2):133-40. PubMed ID: 11426614
[TBL] [Abstract][Full Text] [Related]
10. A case of relapsed meningeal Burkitt's leukemia/lymphoma treated with intraventricular rituximab combined with high-dose cytarabine.
Billio A; Svaldi M; Morello E; Amato B; Coser P
Am J Hematol; 2006 Oct; 81(10):798-9. PubMed ID: 16838326
[No Abstract] [Full Text] [Related]
11. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
12. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review.
Motl SE; Baskin RC
Pharmacotherapy; 2005 Aug; 25(8):1151-5. PubMed ID: 16207108
[TBL] [Abstract][Full Text] [Related]
13. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
15. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
Al-Ali HK; Wittekind C; Niederwieser D
Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon.
Ram R; Bonstein L; Gafter-Gvili A; Ben-Bassat I; Shpilberg O; Raanani P
Am J Hematol; 2009 Apr; 84(4):247-50. PubMed ID: 19260124
[TBL] [Abstract][Full Text] [Related]
18. [Successful salvage therapy with cladribine and rituximab for a patient with a relapsed Asian variant of intravascular large B-cell lymphoma].
Tsujimura A; Miyamura K; Kuwatsuka Y; Inamoto Y; Tokunaga M; Oba T; Terakura S; Suzuki R; Ito M; Murase T; Kodera Y
Rinsho Ketsueki; 2006 Oct; 47(10):1387-92. PubMed ID: 17094579
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
20. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
Perceau G; Diris N; Estines O; Derancourt C; Lévy S; Bernard P
Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
